NZ628529A - Fraction i-iv-1 precipitation of immunoglobins from plasma - Google Patents

Fraction i-iv-1 precipitation of immunoglobins from plasma

Info

Publication number
NZ628529A
NZ628529A NZ628529A NZ62852913A NZ628529A NZ 628529 A NZ628529 A NZ 628529A NZ 628529 A NZ628529 A NZ 628529A NZ 62852913 A NZ62852913 A NZ 62852913A NZ 628529 A NZ628529 A NZ 628529A
Authority
NZ
New Zealand
Prior art keywords
suspension
precipitation
immunoglobulins
fraction
cohn pool
Prior art date
Application number
NZ628529A
Other languages
English (en)
Inventor
Hans-Peter Schwarz
Leopold Bruckschwaiger
Thomas Gundinger
Julia Nuernberger
Wolfgang Teschner
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47833446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ628529(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of NZ628529A publication Critical patent/NZ628529A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ628529A 2012-02-23 2013-02-25 Fraction i-iv-1 precipitation of immunoglobins from plasma NZ628529A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261602488P 2012-02-23 2012-02-23
PCT/US2013/027681 WO2013126904A1 (en) 2012-02-23 2013-02-25 Fraction i-iv-1 precipitation of immunoglobins from plasma

Publications (1)

Publication Number Publication Date
NZ628529A true NZ628529A (en) 2016-09-30

Family

ID=47833446

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628529A NZ628529A (en) 2012-02-23 2013-02-25 Fraction i-iv-1 precipitation of immunoglobins from plasma

Country Status (25)

Country Link
US (1) US9782477B2 (https=)
EP (2) EP2817334B1 (https=)
JP (1) JP6291423B2 (https=)
KR (1) KR101930582B1 (https=)
CN (1) CN104245730B (https=)
AR (1) AR090425A1 (https=)
AU (1) AU2013203112B2 (https=)
BR (1) BR112014020602B1 (https=)
CA (1) CA2864715A1 (https=)
CL (1) CL2014002225A1 (https=)
CO (1) CO7081143A2 (https=)
DK (1) DK2817334T3 (https=)
EA (1) EA032478B1 (https=)
ES (1) ES2928954T3 (https=)
HU (1) HUE060195T2 (https=)
IL (1) IL234103B (https=)
MX (2) MX365236B (https=)
MY (1) MY167235A (https=)
NZ (1) NZ628529A (https=)
PL (1) PL2817334T3 (https=)
PT (1) PT2817334T (https=)
SG (1) SG11201405149UA (https=)
SI (1) SI2817334T1 (https=)
TW (1) TWI629283B (https=)
WO (1) WO2013126904A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN104004090A (zh) * 2014-06-12 2014-08-27 新疆德源生物工程有限公司 一种人免疫球蛋白的制备方法
CN104004091B (zh) * 2014-06-12 2016-08-17 新疆德源生物工程有限公司 一种人免疫球蛋白的制备工艺
GB201413227D0 (en) * 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
WO2017025965A1 (en) * 2015-08-13 2017-02-16 Kamada Ltd. Compositions derived from cohn fraction paste and use thereof
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
WO2019219890A1 (en) * 2018-05-17 2019-11-21 Csl Behring Ag Method and system of protein extraction
EP4061826A1 (en) 2019-11-20 2022-09-28 CSL Behring AG Method for extracting a protein from a precipitate and method for precipitating impurities
US11732004B2 (en) * 2020-04-10 2023-08-22 Plasma Technologies, Llc Compositions and methods for simplified high efficiency isolation of proteins
JP2025512143A (ja) * 2020-11-09 2025-04-17 武田薬品工業株式会社 酸化ケイ素吸着を使用する血漿からのｆｖｉｉｉの精製
CN112250757A (zh) * 2020-11-13 2021-01-22 广东深蓝生物科技有限公司 一种猪血浆中蛋白质的提取纯化方法
US11884702B2 (en) * 2020-12-28 2024-01-30 Plasma Technologies, Llc Systems and methods for process scale isolation of immunoglobulin G
CN118580342B (zh) * 2024-05-20 2025-02-07 广东丹霞生物制药有限公司 一种静脉注射用人免疫球蛋白制剂的制备工艺

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (https=) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US3998946A (en) 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
JPS5855432A (ja) * 1981-09-29 1983-04-01 Fujirebio Inc 静脈注射用免疫グロブリンの製法
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
US6284874B1 (en) 1994-06-17 2001-09-04 Alpha Therapeutic Corporation Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
TW541179B (en) 1997-03-19 2003-07-11 Green Cross Corp Process for preparing immunoglobulin preparation
GB9705810D0 (en) * 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
CN1149100C (zh) 1997-10-23 2004-05-12 三菱制药株式会社 可室温贮存的免疫球蛋白静脉注射制剂
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US7038775B2 (en) * 2001-07-05 2006-05-02 Hamamatsu Photonics K.K. Spectroscopic device
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
PT1664123E (pt) 2003-09-22 2008-07-16 Kamada Ltd Preparação em larga escala de um inibidor da alfa-1 proteinase e sua utilização
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
WO2008113589A1 (en) 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
TWI445714B (zh) * 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法
AT516600B1 (de) * 2009-07-23 2016-07-15 Baxter Int Herstellung von faktor h (fh) und fh-derivaten aus plasma
WO2011150284A2 (en) * 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
ES2717177T3 (es) 2010-07-23 2019-06-19 Baxalta GmbH Fabricación de proteínas inhibidoras inter-alfa (IaIp) a partir de plasma

Also Published As

Publication number Publication date
HK1205520A1 (en) 2015-12-18
US20130224183A1 (en) 2013-08-29
IL234103B (en) 2019-11-28
CO7081143A2 (es) 2014-10-10
MX365236B (es) 2019-05-28
BR112014020602B1 (pt) 2022-12-20
AR090425A1 (es) 2014-11-12
MX2014010076A (es) 2014-09-22
SG11201405149UA (en) 2014-09-26
ES2928954T3 (es) 2022-11-23
KR20140135996A (ko) 2014-11-27
PL2817334T3 (pl) 2022-11-21
JP2015509506A (ja) 2015-03-30
SI2817334T1 (sl) 2022-11-30
CN104245730A (zh) 2014-12-24
DK2817334T3 (da) 2022-10-03
EP4119574A1 (en) 2023-01-18
BR112014020602A2 (pt) 2018-09-11
AU2013203112A1 (en) 2013-09-12
PT2817334T (pt) 2022-10-17
AU2013203112B2 (en) 2016-03-10
KR101930582B1 (ko) 2018-12-18
CA2864715A1 (en) 2013-08-29
EP2817334B1 (en) 2022-09-21
IL234103A0 (en) 2014-09-30
WO2013126904A1 (en) 2013-08-29
EP2817334A1 (en) 2014-12-31
CN104245730B (zh) 2017-09-01
JP6291423B2 (ja) 2018-03-14
MY167235A (en) 2018-08-14
EA032478B1 (ru) 2019-06-28
MX2019005999A (es) 2019-08-21
TWI629283B (zh) 2018-07-11
CL2014002225A1 (es) 2015-01-16
HUE060195T2 (hu) 2023-02-28
TW201348248A (zh) 2013-12-01
US9782477B2 (en) 2017-10-10
EA201491564A1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
NZ628529A (en) Fraction i-iv-1 precipitation of immunoglobins from plasma
EP3564259A3 (en) Recognition tags for tgase-mediated conjugation
WO2013092983A3 (en) Enzymatic conjugation of polypeptides
WO2014125374A3 (en) Highly galactosylated anti-tnf-alpha antibodies and uses thereof
WO2012017324A3 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
AR076800A1 (es) Metodo para producir una preparacion de inmunoglobulina con un alto rendimiento
NZ618067A (en) Anti-cd100 antibodies and methods for using the same
MX389274B (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano.
EP2522724A4 (en) POLYPEPTIDE MODIFYING METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
MX2018000344A (es) Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano.
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
PH12016500158A1 (en) Methods for controlling fucosylation levels in proteins
WO2012112419A8 (en) Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
EA201592189A1 (ru) Способ и установка для производства железа из пиритных огарков
MY158522A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory diseases or condition
SG10201804515YA (en) Method for producing high-quality recombinant allergens in a plant
EP3048112A4 (en) Fc-BINDING PROTEIN, METHOD FOR PRODUCING SAID PROTEIN, AND ANTIBODY ADSORBENT USING SAID PROTEIN, AND METHODS FOR PURIFYING AND IDENTIFYING ANTIBODY USING SAID ADSORBENT
WO2013026021A3 (en) Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease
NZ599840A (en) Sequence dependent aggregation
WO2012062724A3 (de) Aufbereitung eines aminbasierten, durch den eintrag von schwefeloxiden verunreinigten lösungsmittels
ATE541858T1 (de) Präparation von intravenösem immunglobulin mit ultrahoher ausbeute
MX2013011906A (es) Metodos para purificar hidrofobina.
EP2492689B8 (en) Detection of antibodies using an improved immune complex (IC) ELISA
WO2012047037A3 (ko) 배아줄기세포 유래 심근세포 및 이를 유효성분으로 포함하는 세포치료제

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: BAXALTA INC, US

Effective date: 20160414

Owner name: BAXALTA GMBH, CH

Effective date: 20160414

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 FEB 2018 BY COMPUTER PACKAGES INC

Effective date: 20170318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 FEB 2019 BY ANAQUA SERVICES

Effective date: 20180122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 FEB 2020 BY ANAQUA SERVICES

Effective date: 20190122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 FEB 2021 BY ANAQUA SERVICES

Effective date: 20200121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 FEB 2022 BY ANAQUA SERVICES

Effective date: 20210120

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20210330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 FEB 2023 BY ANAQUA SERVICES

Effective date: 20220119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 FEB 2024 BY ANAQUA SERVICES

Effective date: 20230120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 FEB 2025 BY ANAQUA SERVICES

Effective date: 20240123

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 FEB 2026 BY ANAQUA SERVICES

Effective date: 20250122